直接作用的口服抗凝剂达比加特兰作为桥梁疗法,同时优化对心血管栓塞性中风的华法林剂量
Narayanaswamy Venketasubramanian1, Yohanna Kusuma2,3,4,5, Leonard Leong Litt Yeo6
1Raffles Neuroscience Centre, Raffles Hospital, Singapore, Singapore.
Cerebrovascular diseases extra
|December 22, 2024
概括
直接作用的口服抗凝剂 (DOAC),如达比加特兰,在预防中风的华法林启动期间是有效的桥梁治疗. 这种方法比肝素具有优势,包括口服,并可能降低出血风险.
科学领域:
- 神经学 神经学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 亲腔肝素是口服抗凝剂 (OAC) 启动的标准桥梁疗法.
- 直接作用的口服抗凝剂 (DOAC) 提供快速的治疗效果.
- 华法林经常被选择用于二次中风预防的长期抗凝药.
研究的目的:
- 报告在华法林优化期间使用达比加特兰作为桥梁治疗.
- 评估这种新的桥梁策略在心血管栓塞性中风患者中的可行性和安全性.
主要方法:
- 两名患有心血管血栓性中风和心房的患者的病例报告.
- 开始使用华法林与达比加特兰的桥梁疗法.
- 监测国际规范化比率 (INR) 用于华法林优化.
- 一旦达到治疗INR,停止使用达比加特兰.
主要成果:
- 在这两名患者中,达比加特兰桥梁成功地被使用.
- 用华法林实现了治疗性INR水平.
- 在随访期间,患者没有出现出血或复发性缺血事件.
结论:
- DOACs,如达比加特兰,在OAC优化期间可用于桥梁治疗.
- 与肝素相比,其优势包括口服,成本较低,并可能降低出血风险.
- 这一策略可能适用于各种血栓状况,包括中风,DVT和PE.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
608
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
608
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
467
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
467
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
775
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
775
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
Therapeutic Index
4.1K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.1K


